PM360

MAY 2, 2023

Ardelis Health , a healthcare strategic marketing agency and consulting firm partnering with innovators that discover, differentiate, and launch important therapies, today announced the appointment of industry veteran Timmy Garde as Chief Growth Officer. “We We are thrilled to welcome Timmy to the Ardelis leadership team.

Food and Drug Administration 52

Food and Drug Administration Healthcare Healthcare Biopharma 52

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.

Patients 59

Patients Pharma Education Media 59

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. Chief executive officer of Chiesi Group , Marco Vecchia, said: “This addition of the Amryt portfolio, as well as their expertise, will help us on our journey to bring medicines to patients, no matter how rare their condition may be.”. in an all-cash transaction at $14.50

Pharma 87

Pharma Biopharma Management Medicine 87

Medico Reach

AUGUST 1, 2022

Whether you are a start-up looking for investment or are interested in working in venture capital (VC), the worldwide biopharma and MedTech industries are growing. In 2022, over $14 billion was funded in biopharma setup globally, and 37 major IPOs of VC-backed biotech company businesses raised a combined $4.2 New Enterprise Associates.

Biopharma 52

Biopharma Healthcare Healthcare Specialization 52

Clarivate

MAY 24, 2022

Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. Mainland China has taken significant steps toward improving access to treatment for its estimated 20 million rare disease patients in recent years. [1]

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

Pharma Marketing Network

MARCH 25, 2022

But one key member is often omitted: the patient’s caregiver. With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. The FDA has studied the importance of caregivers to drug development and regulatory decision-making. The Caregiver Composite.

Pharma 98

Pharma Education Transportation Training 98

Clarivate

NOVEMBER 23, 2021

Learnings from bringing clinical trial management in-house, and how to modernize your approach to patient-first trials with advanced data science, real-world data and other patient intelligence. Clearly, making sure that we’ve got the right patients and principal investigators is still a challenge.

Patients 52

Patients Recruitment Management Healthcare 52

Clarivate

JANUARY 8, 2024

These new treatments hold tremendous promise to advance patient care and fuel the next generation of medical breakthroughs. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. Common themes for this year’s picks included: New drugs developed using new modalities and technologies.

Marketing 59

Marketing Patients Healthcare Healthcare 59

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality. The industry is moving at an unprecedented speed. Cold chain logistics, meanwhile, have never been so important.

Medicine 98

Medicine Transportation Manufacturing Biopharma 98

PM360

DECEMBER 14, 2023

A New Online Destination for HCPs HealthCentral Corporation , operator of leading digital platforms that serve patients living with chronic illness, their care partners, and health professionals, has announced the newest addition to its suite of HCP support sites: MedCentral.

Physicians 52

Physicians Pharma Medical Patients 52

Clarivate

AUGUST 2, 2022

Four major trends came to light from CIRS’ most recent analysis of new active substance (NAS) approvals for the European Medicines Agency (EMA), US Food and Drug Administration (FDA), Japanese Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, Swissmedic and the Australian Therapeutic Goods Administration (TGA).

Medicine 98

Medicine Food and Drug Administration FDA Healthcare 98

Clarivate

APRIL 4, 2024

Greater awareness among clinicians could improve early diagnosis and disease management in patients. Because misdiagnoses are relatively frequent for patients with IMIDs, awareness of racial and ethnic variations in IMIDs could aid early diagnosis and improve disease management,” the paper concluded. You can read about the study here.

Electronics 52

Electronics Patients Medical FDA 52

European Pharmaceutical Review

DECEMBER 21, 2022

For example, the MHRA launched its Innovative Licensing and Access Pathway (ILAP) in January 2021 with the goal “…to accelerate the time to market, facilitating patient access to medicines. This US pathway offers early-phase benefits, including greater FDA collaboration. Breakthrough therapy designation. Fast track designation.

Food and Drug Administration 109

Food and Drug Administration Medicine Food Government 109

Pharmaceutical Technology

DECEMBER 12, 2022

On October 31, Actinium Pharmaceuticals announced positive topline results from a Phase III study with Iomab-B , which is being studied to treat patients with active relapsed or refractory acute myeloid leukemia. Previously, Iomab-B received an EMA orphan drug designation for patients with this condition.

Manufacturing 59

Manufacturing Biopharma Pharmaceutical Pharma 59

Clarivate

JULY 5, 2023

The month of July could see seven FDA-approved adalimumab biosimilars launch in the United States, an unprecedented situation for a market that has been relatively slow to embrace biosimilars. By end of year, as many as ten adalimumab biosimilars could be on the U.S. biologics market and reduce prescription drug costs.

Marketing 97

Marketing Physicians Manufacturing Competition 97

World of DTC Marketing

JUNE 8, 2021

SUMMARY: The approval of Biogen’s Alzheimer’s drug, after its advisory panel turned it down, begs the Inspector General to open an investigation into the FDA. The FDA gave approval to a medication despite a strong NO vote from their advisory panel of scientific advisers. Where to start? Nowhere to be seen.

FDA 207

FDA Food and Drug Administration Patients Biopharma 207

Clarivate

OCTOBER 30, 2022

Half of the psychiatrists surveyed reported having prescribed or recommended DTx to patients within the three studied indications, while the remainder indicated they expect or are open to prescribing them. As a result, few products have FDA clearance. Payers and providers embrace evidence-based DTx. What’s next?

Insurance 52

Insurance FDA Prescription Marketing 52

Clarivate

NOVEMBER 14, 2023

Well, it is, but only if it benefits patients. 2] Advances in blood glucose monitoring and in the delivery of insulin through insulin pens and, more recently, pumps have also helped to make diabetes management easier for patients. 6] GLP-1 RAs provide another example of the benefits that incremental innovation can bring to patients.

Food and Drug Administration 52

Food and Drug Administration Medicine Patients Food 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

pharmaphorum

SEPTEMBER 12, 2022

Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. The test is conducted in a care provider’s office or our patient service centres (PSC). Tailored oncology.

Patients 101

Patients Medicine FDA Healthcare 101

Clarivate

OCTOBER 19, 2023

The most important benefit is that it can deliver efficacious therapeutics to patients awaiting treatment much faster. the FDA offers a period of 3 years of data exclusivity for a new application of a previously approved drug. For example, in the U.S.,

Networking 59

Networking Consulting Safety Side effects 59

Clarivate

MAY 24, 2023

A narrow FDA AdComm vote in favor of accelerated approval for Sarepta’s first-in-class gene transfer therapy illustrates challenges faced by regulators, payers and developers as a wave of innovative genetic treatments for rare diseases comes to market. Most patients must use a wheelchair by the time they are in their teens.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? I believe this is going to be an emerging trend in the market.

Manufacturing 80

Manufacturing Food and Drug Administration Biopharma Marketing 80

MedCity News

JUNE 12, 2023

One of the fastest-growing frontiers of healthcare is Digital Therapeutics (DTx), which utilizes clinically tested software to prevent, treat, and manage a growing range of medical conditions. The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities.

Food and Drug Administration 86

Food and Drug Administration Prescription Government FDA 86

Clarivate

MARCH 17, 2022

Experts at a November 2021 Food and Drug Administration (FDA) meeting also wrestled with this theme of clinical trials and pregnancy. Ahead of the meeting, the FDA highlighted nonclinical findings (i.e., We look at the outcome of a recent Food and Drug Administration meeting and their draft guidance for more information.

Food and Drug Administration 10

Food and Drug Administration Safety FDA Ethics 10

Clarify Health

MAY 19, 2020

The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. After FDA-approval comes the last critical mile of this journey: bringing the product to market. Which physicians see these patients?

Biopharma 52

Biopharma Physicians Marketing Prescription 52

pharmaphorum

JANUARY 13, 2023

AstraZeneca’s first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves. million patients worldwide with severe asthma who are uncontrolled, without any phenotypic and biomarker limitation.

Sales 57

Sales Biopharma Healthcare Provider Patients 57

pharmaphorum

JANUARY 6, 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Patient choice will push sponsors toward operational excellence.

Safety 106

Safety Management Patients Biopharma 106

Legacy MEDSearch

MAY 19, 2023

PaceMate ® announced today its collaboration with AliveCor ® , the global leader in FDA-cleared personal electrocardiogram technology and remote patient management solutions for the cardiovascular industry. We are proud to be the pioneer in remote cardiac management.”

Healthcare Provider 52

Healthcare Provider Management Healthcare Healthcare 52

European Pharmaceutical Review

OCTOBER 19, 2023

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. These diagnostics have significantly progressed based on rigorous Phase III trial designs and because of the impact these diagnostics have had on patient management.

Food and Drug Administration 90

Food and Drug Administration Side effects Manufacturing Doctors 90

PM360

JULY 13, 2023

However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. Cellectis is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.

Patients 98

Patients Engineering Side effects Leads 98

Clarivate

NOVEMBER 8, 2022

We feel that a cure for cancer or to changing cancer patients’ lives is in our grasp,” Tureci said in the BBC interview. . RNA therapeutics actually burst onto the scene prior to the COVID-19 pandemic, with the FDA approval of Ionis/Biogen’s SPINRAZA®, for the treatment of spinal muscular atrophy, in 2016. Cargene Biopharma Inc.,

Pharma 52

Pharma Biopharma FDA Marketing 52

Clarivate

OCTOBER 7, 2021

Clarivate oncology experts share major takeaways from ESMO and their expected impact on the treatment landscape and patients. In the following article, we present our analysis of these abstracts and key takeaways for healthcare executives. Context: In August 2021, Merck & Co. Context: In August 2021, Merck & Co.

Patients 91

Patients Safety Marketing Physicians 91

Medgadget

FEBRUARY 17, 2023

All of these systems operate under the “master-slave” concept, which involves a surgeon sitting behind a console, away from the patient, who manipulates the mechanical arms of the robot via some kind of joystick-like device.

Physicians 80

Physicians Engineering Side effects Leads 80

Medgadget

MARCH 2, 2023

The first human trial done in Israel proved very successful (2017-2018, finalized during COVID), and published in the Red Journal , the official journal of the American Society for Radiation Oncology), involving many patients whose cancer recurred after treatment or whose options were exhausted. The rest of the patients had partial responses.

Manufacturing 83

Manufacturing Leads Patients Medicine 83

Pharmaceutical Technology

MARCH 21, 2023

FDA and EMA decisions In January, the European Commission (EC) approved Roche’s Xofluza (baloxavir marboxil) to prevent and treat influenza in children ages one year and older. Regulatory decisions by the FDA and EMA for select therapies from late January to late February and the CMOs contracted to manufacture the therapies.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59

Pharmaceutical Technology

JANUARY 15, 2023

On November 30, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) awarded a Great Britain marketing authorization to Aurinia Pharmaceuticals’ Lupkynis (voclosporin) for the treatment of lupus nephritis. FDA expands approval labels. Source: GlobalData Pharmaceutical Intelligence Center.

Manufacturing 52

Manufacturing Pharmaceutical FDA Pharma 52